Did a Personalized Vaccine Keep Kidney Cancer Patients Cancer-Free? What the Instagram Post Leaves Out

An October 2026 Instagram post from @hashem.alghaili says a personalized cancer vaccine "kept all kidney cancer patients entirely cancer-free." It describes a phase I trial of nine patients with advanced clear cell renal cell carcinoma. It names Dana-Farber, Harvard and Yale, says follow-up was about 3.4 years with no recurrences, and cites a Nature paper by Braun, Keskin, Choueiri, Ott and colleagues.

View the original post

What's real

The study exists. It is "A neoantigen vaccine generates antitumour immunity in renal cell carcinoma," published in Nature in 2025 (PubMed lists it as PMID 39910301). It was an investigator-initiated phase I trial (NCT02950766) led by Dana-Farber Cancer Institute researchers.

The numbers in the post match what we found in the Dana-Farber news release and a trade-press summary. Nine patients had stage III or IV clear cell renal cell carcinoma that had been fully removed by surgery. None of the nine had a recurrence at the last follow-up. Trade press (Targeted Oncology) reports a median follow-up of 40.2 months after surgery, which is about 3.4 years. The Dana-Farber release gives a median of 34.7 months, which likely counts from a different starting point. We could not confirm why the two figures differ.

The vaccine is made for each person. Researchers study the patient's own tumor, find mutations that make "neoantigens" (protein pieces found on the tumor but not on normal cells), and pick up to five to build the vaccine. Five of the nine patients also got an immunotherapy drug, ipilimumab, given near the injection site.

What's missing or wrong

"Kept all patients cancer-free" says the vaccine caused the result. This study cannot show that.

• Only nine people. A result in nine patients can be luck. It tells us little about how well this would work in the many people with kidney cancer.
• No comparison group. Nobody was randomly assigned to get no vaccine. Without that, we cannot tell how many of these patients would have stayed cancer-free anyway. Some people with stage III disease never have a recurrence after surgery.
• "Cancer-free" is not "cured." Kidney cancer can come back many years after surgery. Three to four years of follow-up is encouraging but not a final answer.
• Phase I trials test safety first. The main goal was to see whether the vaccine is safe and whether it triggers an immune response. Recurrence was not a proven endpoint.
• "Advanced" needs context. These patients had their tumors removed first. The vaccine was given afterward to try to lower the chance of return. It was not tested as a treatment for cancer that was still growing.

What the evidence says

According to the trade-press summary of the paper, no patient had a dose-limiting toxicity. Every patient had a reaction at the injection site. Eight of nine had brief flu-like symptoms. No serious (grade 3 or higher) side effects were reported.

The immune results were strong. All nine patients developed T cell responses (immune cells that can attack cancer) against vaccine targets. Dana-Farber reports that vaccine-related T cells increased on average 166-fold and stayed high for up to three years.

Immune responses are not the same as outcomes. A vaccine can raise T cells that never stop a cancer from returning. The only way to know is a larger randomized trial. One is under way. INTerpath-004 (NCT06307431) is a phase 2 study comparing a personalized vaccine plus pembrolizumab with placebo plus pembrolizumab after surgery for kidney cancer. Its results are not out. We did not open its results because none were found.

The Dana-Farber release lists funding from Gateway for Cancer Research, the Department of Defense, the National Institutes of Health, Dana-Farber/Harvard Cancer Center and private foundations. We could not open the full paper to read the conflict-of-interest statements.

What to do with this

This is good early news, and it is fair to call it promising. It is not a vaccine you can get today. It is not approved by the FDA for kidney cancer.

If you or someone you love has kidney cancer, the best next step is to ask the care team about standard care after surgery and whether a clinical trial fits. Our guides on finding a clinical trial and what trial results mean can help you prepare questions. Do not delay or change treatment because of a social media post.

If you are on immunotherapy and have a fever of 100.4 F (38 C) or higher, call your care team right away. For an emergency such as trouble breathing, call 911.

Sources

• Dana-Farber Cancer Institute, "Cancer vaccine shows promise for patients with stage III and IV kidney cancer" (2025): dana-farber.org
• Targeted Oncology, "No RCC Recurrence in Patients Treated With Adjuvant Neoantigen Vaccine" (February 2025): targetedonc.com
• Braun DA, et al. "A neoantigen vaccine generates antitumour immunity in renal cell carcinoma." Nature, 2025 (PubMed PMID 39910301): pubmed.ncbi.nlm.nih.gov. The Nature page itself would not open for us, so we did not read the full paper.
• National Cancer Institute, "Kidney Cancer": cancer.gov
• National Cancer Institute, "Immunotherapy to Treat Cancer": cancer.gov

How this article was prepared

An AI-assisted editorial system helped prepare this page. It used the Dana-Farber news release, a trade-press summary of the Nature paper and the PubMed record. The full Nature paper would not open, so some details come from those summaries. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.